Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 27, 2014 | Director | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 10,000 | -- | -- | |
| Aug 25, 2014 | Chief Operating Officer | Open market or private purchase of non-derivative or derivative security | Form 4 | 7,000 | $6.00 | 207,000 | |
| Aug 25, 2014 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 7,000 | $6.00 | 200,000 | |
| Aug 25, 2014 | Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 7,000 | -- | 78,000 | |
| Aug 25, 2014 | VP, Technical Operations | Open market or private purchase of non-derivative or derivative security | Form 4 | 7,000 | $6.00 | 57,000 | |
| Aug 25, 2014 | VP, Technical Operations | Open market or private sale of non-derivative or derivative security | Form 4 | 7,000 | $6.00 | 50,000 | |
| Aug 25, 2014 | VP, Technical Operations | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 7,000 | -- | 28,000 | |
| Aug 25, 2014 | VP, Patient Advocacy | Open market or private purchase of non-derivative or derivative security | Form 4 | 5,000 | $6.00 | 55,000 | |
| Aug 25, 2014 | VP, Patient Advocacy | Open market or private sale of non-derivative or derivative security | Form 4 | 5,000 | $6.00 | 50,000 | |
| Aug 25, 2014 | VP, Patient Advocacy | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | -- | 5,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.